Double‐bright (CD56bright/CD16bright) natural killer cell adoptive immunotherapy for SARS‐CoV‐2

Silla, Lúcia Mariano da Rocha

doi:10.1111/bjh.17010

Cited by 4 publications

(3 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, transfusion need is not higher in patients administered with prophylactic LMWH doses, therefore confirming that this scheme is safe. However, number of transfusions are significantly and independently associated with mortality (OR 1.32, 95% CI 1.01–1.72), as previously reported in other studies [ 32 , 33 ]. Therefore, we agree with those who suggest to use restrictive thresholds for RBC in COVID-19 patients, although clinicians may have the temptation to choose intervention over caution in critically-ill patients [ 34 ].…”

Section: Discussionsupporting

confidence: 83%

Use of low-molecular weight heparin, transfusion and mortality in COVID-19 patients not requiring ventilation

Tiscia

Pesavento

Laurenzo

et al. 2021

J Thromb Thrombolysis

View full text Add to dashboard Cite

It is still debated whether prophylactic doses of low-molecular- weight heparin (LMWH) are always effective in preventing Venous Thromboembolism (VTE) and mortality in COVID-19. Furthermore, there is paucity of data for those patients not requiring ventilation. We explored mortality and the safety/efficacy profile of LMWH in a cohort of Italian patients with COVID-19 who did not undergo ventilation. From the initial cohort of 422 patients, 264 were enrolled. Most (n = 156, 87.7%) received standard LMWH prophylaxis during hospitalization, with no significant difference between medical wards and Intensive Care Unit (ICU). Major or not major but clinically relevant hemorrhages were recorded in 13 (4.9%) patients: twelve in those taking prophylactic LMWH and one in a patient taking oral anticoagulants (p: n.s.). Thirty-nine patients (14.8%) with median age 75 years. were transfused. Hemoglobin (Hb) at admission was significantly lower in transfused patients and Hb at admission inversely correlated with the number of red blood cells units transfused ( p < 0.001). In-hospital mortality occurred in 76 (28.8%) patients, 46 (24.3%) of whom admitted to medical wards. Furthermore, Hb levels at admittance were significantly lower in fatalities (g/dl 12.3; IQR 2.4 vs. 13.3; IQR 2.8; Mann–Whitney U-test; p = 0.001). After the exclusion of patients treated by LMWH intermediate or therapeutic doses (n = 32), the logistic regression showed that prophylaxis significantly and independently reduced mortality (OR 0.31, 95% CI 0.13–0.85). Present data show that COVID-19 patients who do not require ventilation benefit from prophylactic doses of LMWH.

show abstract

Section: Discussionsupporting

confidence: 83%

Use of low-molecular weight heparin, transfusion and mortality in COVID-19 patients not requiring ventilation

Tiscia

Pesavento

Laurenzo

et al. 2021

J Thromb Thrombolysis

View full text Add to dashboard Cite

show abstract

“…As mentioned previously, the graft-versus-tumor effect of allogeneic NK cells may be maximized by selecting for KIR mismatch. 51 Although the benefit of KIR-mismatched NK cells in leukemias is relatively well documented, [52][53][54][55][56] more clinical and preclinical studies are needed to demonstrate the benefit of KIR mismatch in pediatric solid tumors. Delgado et al 57 found that osteosarcoma cell lines were most sensitive to allogeneic NK cell lysis when KIR receptor-ligand incompatibility was maximized.…”

Section: Pediatric Mesenchymal Tumorsmentioning

confidence: 99%

Natural Killer Cell Recognition and Control of Epithelial Cancers

Pereira¹,

Carr

Gatti‐Mays

et al. 2022

Cancer J

View full text Add to dashboard Cite

Natural killer (NK) cells possess an innate ability to recognize cancer and are key mediators of cytotoxic efficacy for anticancer antibodies. Recent advances in the ability to generate, qualify, and safely infuse NK cells have led to a wide variety of clinical trials in oncology. Although their efficacy is best established for liquid cancers, their potential application in solid cancers has received increased attention. Here, we provide general background across a disparate group of exemplary solid tumors for which there is evidence for an NK cell role, discuss NK cell recognition motifs specific to each and murine and human studies of each that are supportive of NK cell adoptive immunotherapy, and end with special considerations relevant to the solid tumor microenvironment.

show abstract

“…Continuing these actions, a regional meeting was held on 27 and 28 May, 2021, with the VIII Fani Job Hematology Meeting, coordinated by Professor Lúcia Silla, from Porto Alegre, with a topic exclusively dedicated to CT. Dr. Lúcia is internationally renowned for her dedication to research with Natural Killer (NK) cells [5] but she held an event in a comprehensive way, covering all current aspects, involving Gene Therapy (GT) and CAR-T-cells.…”

mentioning

confidence: 99%